CN102834118A - 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 - Google Patents

包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 Download PDF

Info

Publication number
CN102834118A
CN102834118A CN2011800162176A CN201180016217A CN102834118A CN 102834118 A CN102834118 A CN 102834118A CN 2011800162176 A CN2011800162176 A CN 2011800162176A CN 201180016217 A CN201180016217 A CN 201180016217A CN 102834118 A CN102834118 A CN 102834118A
Authority
CN
China
Prior art keywords
construct
peptide
vaccine
compositions
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800162176A
Other languages
English (en)
Chinese (zh)
Inventor
P·乌尔里希
K·贝尔
G·因贝特
M-J·霍林格
M-E·里弗
A·格拉夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102834118(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102834118A publication Critical patent/CN102834118A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2011800162176A 2010-03-29 2011-03-28 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 Pending CN102834118A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10158273.2 2010-03-29
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06
US61/361,697 2010-07-06
PCT/EP2011/054735 WO2011120924A1 (en) 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410789825.6A Division CN104436212A (zh) 2010-03-29 2011-03-28 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物

Publications (1)

Publication Number Publication Date
CN102834118A true CN102834118A (zh) 2012-12-19

Family

ID=42285305

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800162176A Pending CN102834118A (zh) 2010-03-29 2011-03-28 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物
CN201410789825.6A Pending CN104436212A (zh) 2010-03-29 2011-03-28 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410789825.6A Pending CN104436212A (zh) 2010-03-29 2011-03-28 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物

Country Status (24)

Country Link
US (4) US20130011431A1 (cg-RX-API-DMAC7.html)
EP (1) EP2552489A1 (cg-RX-API-DMAC7.html)
JP (2) JP6088422B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130018407A (cg-RX-API-DMAC7.html)
CN (2) CN102834118A (cg-RX-API-DMAC7.html)
AR (1) AR080810A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011234656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012024708A2 (cg-RX-API-DMAC7.html)
CA (1) CA2793580A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012002685A1 (cg-RX-API-DMAC7.html)
CO (1) CO6630127A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP12012180A (cg-RX-API-DMAC7.html)
GT (1) GT201200265A (cg-RX-API-DMAC7.html)
IL (1) IL221540B (cg-RX-API-DMAC7.html)
MA (1) MA34084B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012011340A (cg-RX-API-DMAC7.html)
NZ (1) NZ601729A (cg-RX-API-DMAC7.html)
PE (1) PE20130642A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501683A1 (cg-RX-API-DMAC7.html)
RU (1) RU2603486C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201505374TA (cg-RX-API-DMAC7.html)
TN (1) TN2012000431A1 (cg-RX-API-DMAC7.html)
TW (2) TW201138805A (cg-RX-API-DMAC7.html)
WO (1) WO2011120924A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535924A (zh) * 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
CN106659736A (zh) * 2014-04-29 2017-05-10 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
CN106659738A (zh) * 2014-04-29 2017-05-10 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
WO2026155574A1 (ko) * 2025-01-15 2026-07-23 주식회사 포스백스 파필로마바이러스 바이러스 유사입자 기반 항-아밀로이드 베타 동물용 백신

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1674934A (zh) * 2002-07-19 2005-09-28 希托斯生物技术股份公司 含有淀粉样β1－6抗原阵列的疫苗组合物
CN101048174A (zh) * 2004-11-05 2007-10-03 诺瓦提斯公司 包含VLP和淀粉样肽β的组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2295740A1 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1674934A (zh) * 2002-07-19 2005-09-28 希托斯生物技术股份公司 含有淀粉样β1－6抗原阵列的疫苗组合物
CN101048174A (zh) * 2004-11-05 2007-10-03 诺瓦提斯公司 包含VLP和淀粉样肽β的组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HONG-DUCK KIM ET AL.: "Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer’s disease", 《IMMUNOLOGY LETTERS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535924A (zh) * 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
CN106659736A (zh) * 2014-04-29 2017-05-10 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
CN106659738A (zh) * 2014-04-29 2017-05-10 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
CN106659738B (zh) * 2014-04-29 2021-02-09 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
US11065273B2 (en) 2014-04-29 2021-07-20 Affiris Ag Treatment and prevention of alzheimer's disease (AD)
US11857568B2 (en) 2014-04-29 2024-01-02 Advantage Therapeutics, Inc. Treatment and prevention of Alzheimer's disease (AD)

Also Published As

Publication number Publication date
US20150297692A1 (en) 2015-10-22
CO6630127A2 (es) 2013-03-01
RU2603486C2 (ru) 2016-11-27
SG10201505374TA (en) 2015-08-28
AU2011234656B2 (en) 2013-08-01
JP2013523682A (ja) 2013-06-17
PH12012501683A1 (en) 2012-11-05
EP2552489A1 (en) 2013-02-06
TW201618806A (zh) 2016-06-01
PE20130642A1 (es) 2013-06-19
US20130011431A1 (en) 2013-01-10
MX2012011340A (es) 2012-11-16
CA2793580A1 (en) 2011-10-06
CN104436212A (zh) 2015-03-25
JP6088422B2 (ja) 2017-03-01
TN2012000431A1 (en) 2014-01-30
JP2017008035A (ja) 2017-01-12
TW201138805A (en) 2011-11-16
CL2012002685A1 (es) 2013-01-25
BR112012024708A2 (pt) 2016-06-07
AR080810A1 (es) 2012-05-09
IL221540B (en) 2018-11-29
US20160101167A1 (en) 2016-04-14
SG183806A1 (en) 2012-10-30
MA34084B1 (fr) 2013-03-05
AU2011234656A1 (en) 2012-10-11
US20140348871A1 (en) 2014-11-27
KR20130018407A (ko) 2013-02-21
WO2011120924A1 (en) 2011-10-06
GT201200265A (es) 2014-03-14
ECSP12012180A (es) 2012-10-30
NZ601729A (en) 2013-10-25
RU2012145734A (ru) 2014-05-10

Similar Documents

Publication Publication Date Title
JP6088422B2 (ja) ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物
CN101141979B (zh) 猫变应原融合蛋白及其用途
US20090123488A1 (en) Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
JP6352251B2 (ja) Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物
JP2023541671A (ja) シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
US8617566B2 (en) Composition comprising VLP and amyloid beta peptide
AU2013221980A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
AU2011253800B2 (en) Composition comprising VLP and amyloid-beta peptide
KR20240082368A (ko) 타우 포스포펩티드 접합체의 안전한 투여 방법
HK1150961A (en) Composition comprising vlp and amyloid-beta peptide
EP2648746A1 (en) Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis Vaccines & Diagnostic

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS VACCINES + DIAGNOSTIC TO: NOVARTIS CO., LTD.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121219